Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
300 participants
INTERVENTIONAL
2022-05-04
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
NCT05934383
Impact of Sympathetic Renal Denervation- a Study in Patients After Renal Transplantation
NCT01899456
Non-invasive Evaluation of Graft Condition in Adult Patients With Kidney Transplant Using Ultrasound Localization Microscopy and Multispectral Optoacoustic Tomography
NCT06472947
Study of the Renal Perfusion in Healthy Volunteers and Renal Transplant Recipients During an Orthostatic Stress
NCT02179411
Non-Invasive Evaluation of Transplant Kidney Using OCT
NCT02084966
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Renal Denervation
Renal Denervation
Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Renal Denervation
Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented daytime ABP ≥135/85 mmHg following 4 week run-in/standardization period on antihypertensive medication regimen
Exclusion Criteria
* Secondary hypertension not including sleep apnea
* Type I diabetes mellitus or uncontrolled Type II diabetes (defined as plasma HbA1c ≥9.0%)
* eGFR \<40
* Brachial circumference ≥42 cm
* Any history of cerebrovascular event or severe cardiovascular event within 3 months prior to consent
* Documented repeat (\>1) hospitalization for hypertensive crisis within 3 months prior to consent
* Documented confirmed episode(s) of unstable angina within 3 months prior to consent
* Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
* Primary pulmonary hypertension
* Night shift workers
* Pregnant, nursing or planning to become pregnant
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ReCor Medical, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Naomi Fisher, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital/Harvard Medical School
Ajay Kirtane, MD, SM
Role: PRINCIPAL_INVESTIGATOR
Columbia University Medical Center/NYPH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiovascular Institute of San Diego
Chula Vista, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Sutter Health
Sacramento, California, United States
Pacific Heart Institute
Santa Monica, California, United States
Bridgeport Hospital
Bridgeport, Connecticut, United States
The Cardiac and Vascular Institute
Gainesville, Florida, United States
Baptist Hospital of Miami
Miami, Florida, United States
Orlando Health
Orlando, Florida, United States
Emory
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Prairie Education and Research Cooperative
Springfield, Illinois, United States
SIU Medicine
Springfield, Illinois, United States
Parkview Research Center
Fort Wayne, Indiana, United States
UnityPoint Health-Des Moines
Des Moines, Iowa, United States
Ochsner Medical Center
New Orleans, Louisiana, United States
Lifebridge Health
Baltimore, Maryland, United States
Tidal Health
Salisbury, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
The Brigham and Women's Hospital
Boston, Massachusetts, United States
UMASS Memorial Medical Center
Worcester, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
Saint Luke's Hospital
Kansas City, Missouri, United States
Renown Regional Medical Center
Reno, Nevada, United States
Cardiovascular Associates of the Delaware Valley
Haddon Heights, New Jersey, United States
NJ Heart & Vascular
Princeton, New Jersey, United States
NYU Langone Hospital - Long Island
Mineola, New York, United States
NYU Langone Health
New York, New York, United States
Columbia University Medical Center/NYPH
New York, New York, United States
Stony Brook University Hospital
Stony Brook, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Cone Health
Greensboro, North Carolina, United States
St. Francis Hospital
Tulsa, Oklahoma, United States
Penn Medicine
Philadelphia, Pennsylvania, United States
UPMC Heart and Vascular Center
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
The University of Texas Health Sciences Center at Houston
Houston, Texas, United States
Texas Tech University Health Sciences Center
Lubbock, Texas, United States
University of Texas Health Sciences Center, San Antonio
San Antonio, Texas, United States
Baylor Scott & White Research Institute
Temple, Texas, United States
Swedish Health Services
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J, Lobo MD, Mahfoud F, Schmieder RE, Sharp ASP, Weber MA, Sapoval M, Fong P, Pathak A, Lantelme P, Hsi D, Bangalore S, Witkowski A, Weil J, Kably B, Barman NC, Reeve-Stoffer H, Coleman L, McClure CK, Kirtane AJ; RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021 Jun 26;397(10293):2476-2486. doi: 10.1016/S0140-6736(21)00788-1. Epub 2021 May 16.
Related Links
Access external resources that provide additional context or updates about the study.
ReCor Medical company website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLN-0932
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.